1. What It Is (Mechanism of Action)

TB-500 is a synthetic fragment containing the actin-binding heptapeptide sequence (Ac-LKKTETQ) of Thymosin Beta-4 ($Teta4$), a 43-amino-acid naturally occurring protein. It acts as an actin-monomer sequestering peptide, regulating cell motility, tissue remodeling, angiogenesis, and inflammatory resolution.

2. Clinical Indications Under Study

Wound healing, myocardial infarction scar remodeling, ophthalmic dry eye syndrome (RGN-259 eye drops), and muscle/tendon repair.

3. FDA Approval & Regulatory Status

Status:Unapproved for Human Use (FDA 503A Category 2 List)

Unapproved for Human Use (FDA 503A Category 2 List)

4. Human Clinical Evidence Summary

While full-length Thymosin Beta-4 has undergone Phase 2 ophthalmic trials for dry eye syndrome (neurotrophic keratitis), the short synthetic TB-500 fragment has not completed randomized clinical trials for systemic musculoskeletal or tissue regeneration in humans.

5. Known Risks, Side Effects & Boxed Warnings

Potent angiogenic properties raise theoretical risks regarding tumor vascularization. Unknown systemic toxicity and immunogenicity profiles. Prohibited by WADA under Category S2 (Peptide Hormones and Growth Factors).

7. Why Gray-Market "Research Chemical" Versions Are Risky

TB-500 is highly vulnerable to mechanical shearing and denaturing. Reconstituting unstable gray-market powders frequently leads to degraded, inactive peptide fragments or contamination with microbial endotoxins.
Peptides Agora Intelligence Wire
Weekly Research Brief

Get Breaking TB-500 (Thymosin Beta-4 Fragment) Clinical Trial Alerts

Receive verified FDA dockets, Phase 3 readouts, and independent HPLC lab audits directly from our medical journalism desk.

HPLC Purity Audits
Independent lab test readouts & endotoxin assays
FDA PCAC Advisory
503A / 503B compounding votes and legal dockets
Phase 2/3 Readouts
Incretin & repair peptide clinical trial data
Zero vendor sponsorship or commercial advertisingUnsubscribe anytime with one click

8. Questions to Ask a Licensed Clinician

If you are discussing this compound with your doctor or healthcare provider, consider bringing these evidence-based questions:

  • Q1: What is the difference between full-length Thymosin Beta-4 and the synthetic TB-500 fragment?
  • Q2: Are there regulated physical therapy or orthopedic biologics with established safety profiles for my injury?

9. Primary Peer-Reviewed Sources & Citations

  • [1] Goldstein AL, et al. Thymosin beta4: a multi-functional regenerative peptide. Basic mechanisms and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed / Source →
  • [2] FDA Bulks Category 2 Substance Review: Thymosin Beta-4 and Derivatives. PubMed / Source →